| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RAIN ONCOLOGY Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| EXELIXIS | 46,940 | -0,10 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |